Plasma Fractionation Market Worth $34.9 Billion by 2024 - Exclusive Report by MarketsandMarkets™

CHICAGO, March 28, 2019 /PRNewswire/ -- According to the new market research report "Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024", published by MarketsandMarkets™, the Plasma Fractionation Market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period.

Don't miss out on business opportunities in Plasma Fractionation Market.

Primarily due to the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period. 

The protease inhibitor segment is expected to grow at the highest CAGR in the plasma fractionation products market during the forecast period.

On the basis of product, the Plasma Fractionation Market is segmented into immunoglobulin, albumin, coagulation factor, protease inhibitor and other plasma products. The protease inhibitor segment is expected to grow at the highest CAGR during the forecast period. Protease inhibitors mainly include alpha-1-proteinase inhibitors, antithrombin, and C-1 esterase inhibitors. The high growth of this segment is majorly due to the increased consumption of tobacco worldwide and the increasing aging population in developing countries, thereby increasing the global burden of COPD and the use of alpha 1-antitrypsin in treatment.

Browse in-depth TOC on "Plasma Fractionation Market"

266 – Tables
51 – Figures 
303 – Pages  

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284

The pulmonology application segment is expected to dominate the Plasma Fractionation Market from 2019–2024.

On the basis of application, the Plasma Fractionation Market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. Immunoglobulin and protease inhibitors are the major plasma products used in the treatment of various respiratory diseases. In recent years, the use of protease inhibitors, such as alpha-1 antitrypsin, has increased significantly, leading the pulmonology application segment to witness the fated growth during the forecast period.

APAC holds high growth potential in the Plasma Fractionation Market.

The APAC is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in the overall healthcare industry, improved economy, increasing number of hemophilic patients, increasing number of organ transplantations, increasing focus on diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products in the region. Moreover, the improving standard of living in several APAC countries has resulted in the increased demand for plasma products.

Inquiry Before Buying:

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=93798284

 Major players in the global Plasma Fractionation Market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China). Geographic expansions and collaborations are the key strategies undertaken by these companies to maintain their positions in the market. 

Browse Adjacent Markets: Pharmaceuticals Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/plasma-fractionation-market.asp 
Visit Our Website: https://www.marketsandmarkets.com